Whalesbook
Bridging the Cost Gap
This trend is driven by the stark financial realities many Indian families face with the high cost of Western immunotherapies. Drugs like Keytruda can cost ₹1-2 lakh per vial, while Opdivo might range from ₹50,000 to ₹100,000. Annual treatment courses can exceed ₹10 lakh, even with assistance programs, pushing 34-84% of patients towards crippling costs according to studies. Chinese-developed alternatives are now entering the market at around ₹50,000 per session, reducing the annual burden to an estimated ₹3.5-4.5 lakh.
Indian Firms Strike Chinese Drug Deals
Indian pharmaceutical companies are actively leveraging these cost advantages through strategic collaborations. Intas Pharmaceuticals has launched serplulizumab, licensed from Shanghai Henlius Biotech, for small cell lung cancer. Glenmark Pharmaceuticals has inked deals for tesilizumab (from Beigene) and trastuzumab rezetecan (from Jiangsu Hengrui), alongside aumolertinib (from Jiangsu Hansoh). Dr. Reddy's Laboratories has partnered with Shanghai Junshi Biosciences for toripalimab, targeting nasopharyngeal carcinoma. These alliances are crucial for bringing innovative, affordable treatments to a vast patient population.
Doctors Back Quality as Access Expands
Concerns regarding the quality and suitability of drugs from China have been addressed by oncologists on the ground. Doctors report that these therapies undergo standard clinical trials and show response rates, progression-free survival, and overall survival comparable to established Western immunotherapy agents. The collaboration between Indian firms and Chinese biotech companies is intensifying, with predictions that Asian-origin medicines could largely replace US and European products within a decade across various therapeutic categories, including cancer, diabetes, and weight loss treatments.